Kimberley R. Doucette, MD, MSC

Provider accepts MedStar Select insurance

Kimberley Doucette, MD, MSC, is fellowship-trained, board-certified medical oncologist and hematologist at MedStar Georgetown University Hospital and the Georgetown Lombardi Comprehensive Cancer Center who specializes in multiple myeloma, leukemia, and myelodysplastic syndrome (MDS).

At MedStar Georgetown, Dr. Doucette specializes in treating all types of plasma cell abnormalities, including:

• Multiple myeloma
• AL Amyloidosis
• Lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia
• Monoclonal gammopathy of undetermined significance (MGUS)
• Smoldering myeloma

Dr. Doucette earned a master’s degree in epidemiology at McGill University in Montreal, Canada, followed by a medical degree at St. George’s University in Grenada. She completed residency training at MedStar Washington Hospital Center and went on to complete a fellowship in hematology oncology at MedStar Georgetown University Hospital. During her final fellowship year, she served as chief fellow in the Department of Hematology and Oncology.

Dr. Doucette’s research interests include plasma cell dyscrasias of all kinds, both cancerous and noncancerous, and related conditions. Her areas of clinical and research focus include multiple myeloma, amyloidosis, MGUS, smoldering myeloma, and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.

She is principal investigator for many of MedStar Georgetown’s multiple myeloma and plasma cell dyscrasia clinical trials, including investigations into multiple myeloma as well as MGUS. Her upcoming trials include refractory multiple myeloma in end-stage renal disease, MGUS associated peripheral neuropathy among others.

Dr. Doucette’s Philosophy of Care

“I am committed to treating each of my patients with respect and dignity. It’s important to me to spend time with my patients, providing compassionate care. At MedStar Georgetown, I hope to give my patients clinical trial opportunities and connect them with the resources they need, so they can get coordinated, comprehensive care at MedStar Georgetown using the latest treatments.

Because blood and marrow transplants are such an important part of treatment for multiple myeloma and related conditions, our department is tightly linked with the blood and marrow transplant team. We have shared clinic space, which enables close collaboration and communication. This streamlines the referral process and gives patients the best chance at an optimal outcome.

Although there is no cure yet for multiple myeloma, with treatment and comprehensive care, patients can typically live active lives. It’s an exciting time to work in myeloma and plasma cell dyscrasias. Research is moving ahead in leaps and bounds, and there are a lot of new treatment options for patients.”

About MedStar Georgetown Cancer Institute
MedStar Georgetown is part of the MedStar Georgetown Cancer Institute, which combines medical expertise, the latest therapies, and research across MedStar Health. Our research engine, the Georgetown Lombardi Comprehensive Cancer Center, is the only National Cancer Institute-designated comprehensive cancer center in the Washington, D.C., region. This partnership means we provide access to cutting-edge clinical trials and the latest breakthroughs in cancer care.

Clinical Trials

AML:

- Phase IB/II of CPX-351 for Relapse Prevention in AML

- BLAST MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

- A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01)

ALL:

- Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Multiple Myeloma:

- A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

- A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01)

- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma